MSCs transplantation. PBMCs from 8 patients were collected and co-cultured with UC MSCs at ratios of 1:1, 10:1 and 50:1, for 24 hours, 48 hours and 72 hours, respectively, to detect the levels of tolerogenic DCs. The FLT3L in the supernatant solution were determined. FLT3L siRNA was added to the co-culture system, and the level of tolerogenic DCs were detected. Results: The levels of peripheral CD1c + DCs and serum FLT3L were significantly decreased in SLE patients compared to healthy controls. After UC MSCs transplantation, the levels of CD1c + DCs increased, along with an increase in serum FLT3L. In vitro studies showed that UC MSCs time-dependently upregulated peripheral CD1c + DCs, but not dose-dependently. The supernatant FLT3L level significantly increased after co-cultured with MSCs. However, the addition of FLT3L siRNA significantly abrogated the up-regulation of CD1c + DCs by MSCs.
Conclusions: AL-λ deposits were present earlier and were more prominent in the skin, heart and kidney, than in the, G-I tract and the lung. Amyloid A deposits were present earlier and were more prominent in the G-I tract, heart and kidney, than in the, lung and the skin. In the brain AL-λ and amyloid A deposits were absent in both diseases. Background: CXCL4 regulates multiple facets of immune response and its level is highly increased in various Th17-associated rheumatic diseases, including systemic sclerosis (SSc) 1-4 . Recently, CXCL4 was shown to induce type I interferon production as well as endothelial activation in SSc patients 1 . Th17 skewing has been demonstrated in SSc 5-6 , however, whether CXCL4 plays a role in the induction of IL-17 production by human CD4 T cells is currently unclear. Objectives: To investigate the effect of CXCL4 on human CD4 T cell phenotype in particular IL-17 production in the absence or presence of antigen presenting cells. Methods: Blood was obtained from healthy donors and CD4 T cells, monocytes, dendritic cells, were isolated using magnetic-based sorting (n=20). In addition, CD4 T cells from SSc patients were isolated (n=10). CD4 T cells were activated using anti-CD3/CD28, or in co-cultures with antigen presenting cells, stimulated using superantigen Staphylococcal enterotoxin B. Exogenous recombinant human CXCL4 was added during (co-)culture in different concentrations. Cytokine production and proliferation were analyzed using Luminex immunoassays, intracellular cytokine staining, and flow cytometry. Results: CXCL4 directly induced CD4 T cells secreting both IL-17 and IFN-γ, as well as IL-22, when costimulated with anti-CD3/CD28 (p<0.05). In many SSc patients, similar IL-17 increase upon CXCL4 treatment was observed, although this did not reach statistical significance. This might be due to the fact that CD4 T cells from SSc patients had already significant higher levels of IL-17 as compared to healthy donors (2182±722.2 vs 1053±263.6 pg/ml, mean±SEM, p<0.05). Furthermore, in co-culture system of CD4 T cells with monocytes or myeloid dendritic cells, CXCL4 treatment induced IL-17 production upon triggering by superantigen (p<0.05). Moreover, when monocyte-derived dendritic cells were differentiated in the presence of CXCL4, they orchestrated significantly increased levels of IL-17, IFN-γ, and proliferation by CD4 T cells (all p<0.05). Conclusions: Altogether, we demonstrate that CXCL4 boosts pro-inflammatory cytokine production especially IL-17 by human CD4 T cells, either by acting directly or indirectly via antigen presenting cells. This indicates that targeting CXCL4 may potentially alleviate immune responses in Th17-mediated rheumatic diseases such as systemic sclerosis. 
